DoD Prostate Cancer Impact Award | Apply Online

Opportunity Summary:

The DoD Prostate Cancer Impact Award (FY15 PCRP Impact Award; Funding Opportunity Number W81XWH-15-PCRP-IA) is a U.S. Army Medical Research Acquisition Activity opportunity under the Congressionally Directed Medical Research Programs (CDMRP) Prostate Cancer Research Program (PCRP). It supports high-impact prostate cancer research projects across the full pipeline, from fundamental laboratory work through translational studies and clinical research, including clinical trials. The central expectation is that the proposed work, if successful, could meaningfully advance the field toward eliminating deaths from prostate cancer and improving quality of life for men affected by the disease. This mechanism has historically been highly selective; since its first offering in FY10, 42 applications were received and 5 were recommended for funding, signaling that applications must be unusually compelling in both significance and potential downstream influence.

The defining feature of this award is "impact." Applicants are expected to make a clear, explicit, and persuasive case that their project addresses an issue of paramount importance in prostate cancer and that the anticipated benefits are substantial rather than incremental. Proposals are strongly encouraged to take on one of the PCRP overarching challenges and must address at least one PCRP focus area. If a project does not align with an overarching challenge, the applicant must justify how it still meets a critical unmet need in prostate cancer research or patient care. Importantly, even when the work is basic science or early-stage, the application must spell out a credible pathway to clinical impact for people who have prostate cancer or are at risk for it. The time horizon can be near-term or long-term, but the program is looking for ideas that could change practice, understanding, or outcomes in a noticeable way, not simply extend existing lines of work.

From a scientific and technical standpoint, the announcement emphasizes study quality and translatability. Applicants are strongly encouraged, where relevant, to build in practices that strengthen reliability and clinical relevance, including authentication of proposed cell lines, strong statistical rigor for preclinical animal experiments, and experiments that directly test clinical relevance or support translation of findings. The program also points applicants toward major shared resources, particularly when human specimens or linked clinical data are important. Two highlighted resources are the PCRP-funded Prostate Cancer Biorepository Network (PCBN) and the North Carolina-Louisiana Prostate Cancer Project (PCaP). The opportunity additionally encourages the use of large patient datasets with long-term health records and biospecimen repositories, especially when paired with modern genomic/proteomic approaches and advanced analytics such as bioinformatics or mathematical modeling.

The scope of eligible research is intentionally broad and multidisciplinary. The PCRP invites applications from investigators spanning basic science, engineering, bioinformatics, population science, translational research, and clinical research. Population science-based approaches are singled out as particularly encouraged, reflecting the program's interest in studies that can explain real-world risk, outcomes, disparities, and intervention impact at scale. Regardless of the domain, applications must include preliminary data demonstrating feasibility, and any unpublished preliminary data must come from the Principal Investigator's laboratory or from a member of the research team, reinforcing that the project is grounded in demonstrated capability rather than purely speculative plans.

A notable requirement of this mechanism is a Data and Research Resource Sharing Plan. The PCRP states an explicit intent that data and research resources created through funded work be shared with the broader research community, including both scientific and consumer advocacy communities, and also with the general public. Applications are therefore expected to outline how unique and/or final datasets will be shared and how any resulting resources (for example, tools, reagents, or other research assets) will be made accessible. This aligns with the program's emphasis on accelerating progress beyond any single lab by enabling reuse, validation, and follow-on discovery.

FY15 also offers a Partnering PI Option designed to support larger, synergistic collaborations with a higher funding level. Under this structure, up to three Principal Investigators may participate: one Initiating PI who leads most of the administrative submission duties and one or two Partnering PIs. The proposal must clearly explain how the combined expertise of the PIs creates synergy that materially increases the likelihood, speed, or magnitude of outcomes compared to separate independent projects. If funded, each PI receives a separate award, which underscores that the collaboration must be genuine, well-integrated, and operationally planned. Multidisciplinary and multi-institutional projects are allowed and encouraged, but they must include explicit interaction plans covering communication, coordination of research progress and results, and data transfer. For multi-institution efforts, an intellectual property plan is required to proactively address potential IP or material ownership issues and to remove institutional barriers that could undermine cooperation.

Administratively, this opportunity is a discretionary award offered as a grant or cooperative agreement in the Science and Technology/Research and Development category, with no cost sharing requirement and eligibility listed as unrestricted (open to any entity type, subject to any additional clarifications in the announcement). For FY15, the estimated total funding is $11.2 million with an expected 6 awards. The opportunity was posted May 20, 2015, and the application closing date was September 24, 2015 (archived October 24, 2015). The CFDA number associated with the program is 12.420 (Military Medical Research and Development). For technical access issues, applicants were directed to the CDMRP Help Desk at 301-682-5507.

Browse more opportunities from the same agency: Dept. of the Army USAMRAA

Browse more opportunities from the same category: Science and Technology and other Research and Development

Next opportunity: DoD Prostate Cancer Idea Development Award

Previous opportunity: DoD Prostate Cancer Exceptional Responders Award

USGrants.org Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for W81XWH 15 PCRP IA

 

[Watch] how do funding administrators access proposals?

Applicants also applied for:

Applicants who have applied for this opportunity (W81XWH 15 PCRP IA) also looked into and applied for these:

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Subscribe to Leads

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "W81XWH 15 PCRP IA", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.